GOVX

GeoVax LabsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$0.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.25

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Recent coverage is mostly company-led and focused on GEO-MVA, Gedeptin, vaccine preparedness, and Ebola-related positioning. Operating updates are constructive, but the disclosed suspension risk materially weakens the near-term setup. Analyst reaction, social coverage, options data, short interest, employee data, and post-release price reaction are unavailable; this remains a low-conviction monitoring view.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-08catalystTrading-suspension riskHigh impact

GeoVax disclosed that, absent a timely hearing request, trading in its securities is expected to be suspended at the opening of business on September 8, 2026. This creates a significant near-term liquidity and price-dislocation risk [#8-K-2026-08-28].

2026-12-02eventGEO-MVA pivotal immunobridging study initiationHigh impact

Management reported continued clinical operations planning, manufacturing preparedness, and regulatory-pathway execution toward planned fourth-quarter initiation of the pivotal GEO-MVA immunobridging study [#SEC-8K-2026-07-27] [#PR-EARNINGS-2026-07-27].

2027-09-03catalystGEO-MVA clinical and regulatory validationHigh impact

Successful study execution and subsequent regulatory or procurement progress could materially improve the value of GEO-MVA, but the packet provides no dated readout or authorization milestone.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology